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Can We Improve the Statistical Analysis of Stroke Trials?
Statistical Reanalysis of Functional Outcomes in Stroke Trials
The Optimising Analysis of Stroke Trials (OAST) Collaboration
Background and Purpose—Most large acute stroke trials have been neutral. Functional outcome is usually analyzed using
a yes or no answer, eg, death or dependency versus independence. We assessed which statistical approaches are most
efficient in analyzing outcomes from stroke trials.
Methods—Individual patient data from acute, rehabilitation and stroke unit trials studying the effects of interventions
which alter functional outcome were assessed. Outcomes included modified Rankin Scale, Barthel Index, and “3
questions”. Data were analyzed using a variety of approaches which compare 2 treatment groups. The results for each
statistical test for each trial were then compared.
Results—Data from 55 datasets were obtained (47 trials, 54 173 patients). The test results differed substantially so that
approaches which use the ordered nature of functional outcome data (ordinal logistic regression, t test, robust ranks test,
bootstrapping the difference in mean rank) were more efficient statistically than those which collapse the data into 2
groups (2; ANOVA, P0.001). The findings were consistent across different types and sizes of trial and for the
different measures of functional outcome.
Conclusions—When analyzing functional outcome from stroke trials, statistical tests which use the original ordered data
are more efficient and more likely to yield reliable results. Suitable approaches included ordinal logistic regression, t
test, and robust ranks test. (Stroke. 2007;38:1911-1915.)
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The management of patients with acute or recent strokehas benefited significantly from the results of random-
ized controlled trials and meta-analyses of these. For exam-
ple, functional outcome is improved with alteplase, aspirin,
management in a Stroke Unit, and community occupational
therapy.1–7 In contrast, some studies were overtly negative
finding that treatment worsened outcome, eg, DCLHb, enli-
momab, selfotel, or tirilazad.8–11 However, the majority of
acute stroke trials were neutral in spite of positive preclinical
findings. The failure of these latter studies can be attributed to
multiple causes, including the relevance of laboratory find-
ings to clinical stroke,12 inadequate sample size,13 choice of
primary outcome, and its statistical analysis.
Measures of functional outcome such as the modified
Rankin Scale (mRS),14 Barthel Index (BI)15 and “3-
questions”16 are ordinal in nature: that is, they consist of 3
categories which have a natural ordering, eg, the mRS has 7
categories ranging from no symptoms to dead. It might then
be expected that statistical analysis would preserve and use
the data in this ordinal form. However, most published trials
have used a “yes/no” (dichotomized) analysis of functional
outcome, eg, combining categories within the mRS into 2
groups, such as “dead or dependent” (eg, mRS 3 to 6) and
“independent” (mRS 0 to 2), and then comparing these
between the treatment groups. Unfortunately, there is little
agreement where mRS data should be divided (ie, 0,1 versus
2 to 6,1 0 to 2 versus 3 to 6,17 or 0 to 3 versus 4 to 6,18) and
whether this matters.19 Furthermore, collapsing data in this
way generally lowers statistical power and therefore reduces
the chance of finding a significant treatment effect because
information from many subjects are ignored. For example,
patients responding to treatment and achieving a mRS of 3
rather than 4 or 0 rather than 1 are not detected in a analysis
comparing mRS 0 to 2 with 3 to 6.
Inadequacies in the statistical analysis of trials in acute
stroke are apparent in 2 examples. First, the ECASS II trial of
alteplase showed no treatment effect for its primary outcome
(when comparing mRS 0,1 with mRS 2 to 6) but was positive
when reanalyzed using the data collapsed in a different place
(mRS 0 to 2 versus 3 to 6)20 or when analyzed using a
“bootstrapping” technique (Figure 1).21 Second, 5 trials of
tirilazad individually showed no treatment effect when ana-
lyzed using dichotomous outcomes22–24 although a meta-anal-
ysis found that the intervention was associated with a worse
outcome25; post hoc analysis then suggested that one of these
trials was negative24 (not neutral) when analyzed using a
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method which preserved the original ordered data (P.B.,
unpublished data, 2004).
We aimed to identify which statistical methods might
optimize the analysis of data from functional outcome scales
in stroke trials.
Methods
Identification of Trials
We sought individual patient data from randomized controlled trials
assessing functional outcome after stroke for interventions which
were either positive or negative according to the trial publication, or
were included in a meta-analysis showing benefit or harm; neutral
trials in a neutral meta-analysis were excluded. Published studies
(full article or abstract) fulfilling these criteria were identified from
electronic searches of the Cochrane Library (to end of 2005). In each
case, we invited the chief investigator to join the collaboration and
share their data. In some cases where individual data could not be
obtained it was possible to extract it from the original publication.
Trial Data
Demographic (age, gender), trial (setting, intervention, length of
follow-up, result), patient severity, and functional outcome (BI,
mRS, “3 question” scale [3Q, a derivative of mRS], or another
measure) data were collected for each trial. In factorial trials or those
having 2 treatment groups, data were analyzed for each compari-
son of active therapy versus control. Where outcome data were
scored at several time points (eg, 1, 3 and 6 months) the time point
used for the primary outcome was included.
Statistical Tests
We compared different statistical tests for assessing treatment effect.
Some of these required the data to be collapsed into groups (such as
the 2 test), whereas others used the original ordinal data (such as
Wilcoxon test and t test). Statistical tests which dichotomized
(“yes/no”) data were assessed multiple times collapsing the data in
different places, eg, mRS 0,1 versus 2 to 6, 0 to 2 versus 3 to 6 and
0 to 5 versus 6. A description of the statistical tests used is given in
the supplemental Appendix I, available online at http://stroke.
ahajournals.org.
Comparison of Statistical Tests
Each data set was analyzed using each statistical test. These results
were then ordered within each trial and given a rank, with the lowest
rank given to the test which produced the most significant result, ie,
the largest z score, within that trial. A 2-way analysis of variance test
was then used to see on average which statistical test had produced
the lowest ranks. We were then able to order the statistical tests in
terms of their efficiency in identifying treatment effects. We also
assessed how many statistically significant (at 5%) results each test
found.
To assess the validity and reliability of the results, a number of
supplementary analyses were carried out. First, the comparison of
statistical tests was repeated within subgroups of trials sharing
similar characteristics; second, the statistical assumptions of the tests
were assessed; and last, the sensitivity of the tests was explored to
make sure treatment effects were only detected when they truly
existed (the type 1 error rate). Technical details of these supplemen-
tary analyses can be found in the supplemental Appendix II,
available online at http://stroke.ahajournals.org.
Analyses were carried out in SAS (version 8.2) and Stata (version 7)
and significance was taken at P0.05.
Results
Trials Characteristics
A total of 55 comparisons of active versus control treatment
(54 173 patients) were included, these comprising individual
patient data from 38 trials and summary data extracted from
the publications of a further 9 studies; 6 trials had 2 active
treatment groups, and 1 had 3 active groups so a further 8
comparisons were available (Figure 2). The data related to 34
acute stroke trials, 7 trials of rehabilitation (1164 patients)
and 6 trials of stroke units (1399 patients). BI was used to
measure functional outcome in 22 trials, 18 used the mRS, 3
used the 3Q scale, 1 used the Rivermead scale, 2 related trials
Figure 1. Distribution in mRS in the ECASS II
trial showing the primary and post hoc
analyses.20
Figure 2. Identification of included trials.
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used the Nottingham ADL scale, and 1 trial used its own
ordinal measure.26 Included trials studied the following inter-
ventions: abciximab (AbESTT); alteplase (ATLANTIS A &
B, ECASS II, NINDS); aspirin (CAST, IST); atenolol
(BEST); citicoline; DCLHb; ebselen; edaravone; enlimomab
(EAST); factor VIIa; feeding (FOOD 3); nadroparin (FISS,
FISS-TRIS); nimodipine (INWEST); occupational therapy
(Corr, Gilbertson, Logan, TOTAL, Walker); physiotherapy
(Young); pro-urokinase (PROACT II); selfotel (ASSIST);
streptokinase (ASK, MAST-E, MAST-I); stroke unit (Dover,
Helsinki, Kuopio, Nottingham, Orpington, Newcastle); and
tirilazad (RANTTAS I & II, STIPAS, TESS I & II). Data
relating to 16 trials or interventions which fulfilled the
inclusion criteria were not made available.
The method of analyzing functional outcome used in the
original trial publication varied considerably, see supplemental
Appendix III, available online at http://stroke.ahajournals.org.
Twenty-three (48.9%) trials assessed the treatment effect
using a method which required the data to be collapsed into
groups, eg, 2 test; 17 (36.2%) used a test based on comparing
medians and 4 (8.5%) used a test which compared means; the
remaining trials were unpublished so the method of analysis
is not known.
Comparison of Statistical Tests
The statistical tests assessed differed significantly in the
results they gave for each trial (2-way ANOVA, P0.0001).
The ordering of the tests showed that those which analyze the
original ordinal data generally perform better than those
which collapse the data into 2 groups. The most efficient
tests included ordinal logistic regression, t test, robust rank
test and bootstrapping the difference in mean rank (Table).
The subgroup analysis showed the same ordering of tests
irrespective of type of intervention (acute, rehabilitation,
stroke unit), trial size, time between randomization and onset,
patient age, baseline severity, outcome measure, length of
follow-up, and trial result (supplemental Appendix IV, avail-
able online at http://stroke.ahajournals.org).
When assessed by how many trials were statistically
significant, those tests which did not collapse the data into
groups again out-performed the other approaches; for exam-
ple, ordinal logistic regression (using raw data) gave a
statistically significant result in 25.9% of trials, whereas the
22 2 test comparing death or poor outcome to an excellent
outcome only gave a significant result in 9.3% of the trials
(Figure 3).
Test Assumptions and Sensitivity
The statistical assumptions of the t test were not met for the
majority of trials, and the assumptions of the ordinal logistic
regression analysis failed for 8 of the 55 data sets; in contrast,
the assumptions for the other tests were maintained. The
sensitivity analysis showed that the top performing statistical
tests were not overly sensitive, and statistically significant
treatment effects were only found where they truly existed;
see supplemental Appendix V, available online at http://
stroke.ahajournals.org, for detailed results.
Discussion
These results show that statistical approaches which analyze
the original ordinal data for functional outcome are more
efficient than those which work on preprocessed data which
has been collapsed into 2 groups. Interestingly, this point
was originally demonstrated mathematically by Shannon in
1948.27 In particular, ordinal logistic regression, t test, robust
ranks test, and bootstrapping (the difference in mean rank)
performed well and appear to be useful irrespective of the
type of stroke trial, patient or intervention. Although individ-
ual tests based on dichotomized data using 2 analysis (eg,
“dead/dependent” versus “independent”) were effective for
some data sets, they performed poorly in many and therefore
cannot be recommended as general solutions for analyzing
stroke trials. From an historical perspective, it is quite
possible that trials which collapsed mRS or BI in 2 groups
may have used a suboptimal analysis, and this may have
contributed to false neutral findings in some cases in the past.
For example, MAST-E28 and STIPAS24 were neutral as
reported using dichotomous analysis but negative when
assessed with ordinal approaches.
Several comments can be made about this study. First, it
aimed to include data from all stroke trials assessing a
beneficial or harmful intervention. Unfortunately, data were
not made available for all identified trials; where possible, we
created individual data from publications which provided
patient numbers by outcome score. Data were missing for a
variety of trial types (acute/rehabilitation/stroke unit) and
Comparison of Rank Scores for 16 Statistical Tests
Comparison of rank scores for 16 statistical tests; lower ranks imply the test
is more efficient. Analysis by two-way ANOVA and Duncan’s multiple compar-
ison procedure; tests joined by the same band are not significantly different
from each other at P0.05.
RRT indicates robust rank test.
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sizes, and functional outcome measure (mRS/BI), so it is
unlikely that a systematic bias was introduced into the
findings; however, the precision of the results may have been
attenuated by the missing trials. Second, we did not exhaus-
tively search for all possible statistical tests relevant to the
problem of analyzing ordered categorical data; instead, we
focused on those approaches which are available in standard
statistical textbooks and computer packages. Additionally, we
could not include some tests used in recent trials, eg, patient
specific outcomes29 and Cochran Mantel-Haenszel test,30
because these require access to individual data for both
baseline and outcome variables, and these data were not
available uniformly. Third, some of the statistical assump-
tions underlying the more efficient tests were not met in all
trials; for example, the t test assumes data are normally
distributed, whereas ordinal logistic regression assumes that
any treatment effect is similar across outcome levels (“pro-
portionality of odds”, ie, the odds of moving a treated patient
from mRS 2 to 1 is similar to that for moving them from 5 to
4). Nevertheless, the robustness of these tests to deviations
from their underlying assumptions means that they remain
relevant for analyzing functional outcome data from stroke
trials.
If alternative approaches to analyzing functional outcome
data are to be used in the future, it is pertinent to ask how
sample size should be calculated at the trial design stage.
Historically, most calculations assumed that functional out-
come would be dichotomized and analyzed using a 2 test
approach.13 Although future trials could continue to calculate
sample size in the same way (and then gain extra power by
analyzing their data using an ordinal approach), specific
sample size calculations are available when data are to be
analyzed using ordinal logistic regression31 or the t test.
Ideally, the extra power gained by using an ordinal statistical
approach should not be used to reduce sample size; stroke
trials have been too small in the past, as shown in a recent
meta-analysis,13 and this may also have contributed to the
failure of some of them.
A further issue with using a statistical test which analyses
ordered categorical data are how to report the results to
patients, carers, clinicians, and health-policy makers. The
results of dichotomous tests may be summarized easily as the
proportion of patients who benefit (or suffer) with a treat-
ment, ie, alteplase reduced absolute death or dependency
(mRS 1) by 13% in the NINDS part 2 trial.1 In contrast,
ordinal tests will need to be presented as the average absolute
improvement in outcome, eg, alteplase improved the mRS by
1 (of 7) point and BI by 22.5 (of 100) points. Alternatively,
the combined odds ratio and its confidence intervals would be
reported if ordinal logistic regression was used. In this
respect, health consumers will need to decide what differ-
ences in mRS and BI are worthwhile, both clinically and in
terms of health economics. In reality, it is reasonable to
present the effect on functional outcome using both abso-
lute percentage change and mean or median change in
functional outcome score, and show this data graphically
(as in Figure 1).
In summary, we suggest that ongoing and future trials
should consider using statistical approaches which use the
original ordered categorical data in the primary analysis of
functional outcome measures. Such ordinal tests include
ordinal logistic regression, and the robust ranks test; the t test
may also be used although its assumptions were not meant in
the majority of trials.
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